GSK Says Potential Blockbuster Helps Treat Common Nasal Disease

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials in a boost for the UK drugmaker’s pipeline.

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population. Of those patients, around 40% have uncontrolled disease, the drugmaker said in a statement Monday.

Shares of GSK rose slightly in early trading. The stock is up 2.3% since the start of the year.

Depemokimab is seen a key part of GSK’s growth ...